Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT04609579 Terminated - Clinical trials for Advanced Solid Tumor

Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma

Start date: November 18, 2020
Phase: Phase 1
Study type: Interventional

This clinical trial is evaluating a drug called SNX281 given by itself and in combination with pembrolizumab (KEYTRUDA®) in participants with advanced solid tumors and lymphoma. The main goals of this study are to: - Find the recommended dose of SNX281 that can be given to participants safely alone and in combination with pembrolizumab (KEYTRUDA®). - Learn more about the side effects and safety profile of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®) - Learn more about pharmacological characteristics of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®) - Learn more about effectiveness of SNX281 alone and in combination with pembrolizumab (KEYTRUDA®)

NCT ID: NCT04602065 Terminated - Clinical trials for Extranodal NK/T Cell Lymphoma, Nasal Type

Evaluation of Safety and Efficacy of IBI318 Monotherapy for Relapsed/Refractory Extranodal NK/T Cell Lymphoma (Nasal Type) Trial

Start date: November 24, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of IBI318 monotherapy for relapsed/refractory extranodal NK/T cell lymphoma (nasal type).

NCT ID: NCT04590820 Terminated - Lymphoma Clinical Trials

Oral Tazemetostat in Combination With Rituximab in R/R FL

Start date: November 17, 2020
Phase: Phase 2
Study type: Interventional

The goal of this study is to examine the feasibility and efficacy of adding the EZH2 inhibitor, Tazemetostat to rituixmab, standard second line or beyond therapy as a means to improve disease response.

NCT ID: NCT04504708 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Start date: February 17, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

ZX-101A-101 is a Phase 1/2a, first-in-human, open-label, multicenter, multiple-ascending dose study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamic, and preliminary antitumor activity of ZX-101A administered orally (PO) once daily (QD) in 28-day cycles in patients with relapsed/resistant or refractory advanced hematologic malignancies [Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL), indolent NHL, and other NHL subtypes).

NCT ID: NCT04502706 Terminated - Clinical trials for Non-hodgkin Lymphoma

Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma

Start date: November 17, 2020
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to determine the safety and tolerability of GS-0189 (formerly FSI-189) as monotherapy and in combination with rituximab in participants with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).

NCT ID: NCT04473937 Terminated - Clinical trials for Hematologic Malignancy

Radiation Post-CAR T in Refractory Lymphoma

Start date: January 5, 2021
Phase: N/A
Study type: Interventional

This study is evaluating the safety and efficacy of using radiotherapy in participants who have refractory lymphoma shortly after receiving CAR T cell therapy (axicel or tisacel).

NCT ID: NCT04465760 Terminated - Lymphoma Clinical Trials

Xisomab 3G3 for the Prevention of Catheter-Associated Thrombosis in Patients With Cancer Receiving Chemotherapy

Start date: February 25, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well xisomab 3G3 works in preventing catheter-associated blood clots (thrombosis) in patients with cancer receiving chemotherapy. Many patients with cancer develop blood clots from their catheters and can have pain, swelling, and other symptoms. They also often require blood thinners, which can increase the risk of bleeding. Xisomab 3G3 is type of drug called a monoclonal antibody that may prevent blood clots caused by a catheter in patients receiving chemotherapy.

NCT ID: NCT04444141 Terminated - Clinical trials for Peripheral T-cell Lymphoma

A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma

Start date: May 15, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of AK104,an anti- PD-1 and CTLA-4 bispecific antibody, in subjects with relapsed or refractory peripheral T cell lymphoma. The subject will receive AK104 450mg Q2W until unacceptable toxicity, confirmed disease progression, withdrawal of consent, or for a maximum of 24 months.

NCT ID: NCT04423848 Terminated - Lymphoma Clinical Trials

Home Hospital for Lymphoma

Start date: June 1, 2020
Phase: N/A
Study type: Interventional

The goal of this research is to evaluate an intervention, which the investigators call "Home Hospital for Lymphoma," that involves remote patient monitoring and home-based supportive care for patients hospitalized with lymphoma at Massachusetts General Hospital.

NCT ID: NCT04419389 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

R/R
Start date: March 2, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

Study to determine the preliminary safety, tolerability, and pharmacokinetic (PK) profile of APR-246 in combination with either acalabrutinib or venetoclax + rituximab therapy in subjects with NHL, including relapsed and/or refractory (R/R) CLL and R/R MCL.